首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

CURRENT CANCER DRUG TARGETS
ISSN：1568-0096

CURRENT CANCER DRUG TARGETS

CURR CANCER DRUG TAR
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：平均1月
新锐分区：医学3区
年发文量：156
影响因子：3.5
JCR分区：Q2

基本信息

《现代癌症药物靶点》旨在涵盖当代癌症分子药物靶点的药物化学、药理学、分子生物学、基因组学和生物化学的所有最新和突出的发展，例如疾病特异性蛋白质、受体、酶和基因。《现代癌症药物靶点》发表原创研究文章、信件、综述/小型综述，药物临床试验研究和客座编辑的主题问题，由该领域的领导人撰写，涵盖了一系列与癌症有关的药物靶标的当前主题。随着用于抗癌药物发现的新的人类药物靶标的发现、鉴定、表征和验证的持续增长;这本杂志已经成为所有参与药物发现和开发的药学科学家的必备阅读。
1568-0096SCIE/Scopus收录
3.5
点击查看最新影响趋势>
2.4
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
ONCOLOGY 肿瘤学
4区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：ONCOLOGY
SCIE
Q2
106/328
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：ONCOLOGY
SCIE
Q3
202/328
85
156
点击查看年发文量趋势图>
27%约50%平均1月-医学-肿瘤学
2.9%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
67.31%5.1%-
CiteScore：4.10
SJR：0.722
SNIP：0.443
学科类别分区排名百分位
大类：Medicine
小类：Oncology
Q2
198 / 415
大类：Medicine
小类：Pharmacology
Q3
175 / 321
大类：Medicine
小类：Drug Discovery
Q3
91 / 156
大类：Medicine
小类：Cancer Research
Q3
147 / 233

期刊高被引文献

Resveratrol as an adjuvant for normal tissues protection and tumor sensitization.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191019143539
Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180430144441
Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666181016145940
Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180628160211
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180319091731
The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666181003170027
Study of Serum Soluble Programmed Death Ligand 1 as a prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190718141647
Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666181016152042
Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009617666170427105417
Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180430123939
Cathepsin L Induces Proangiogenic Changes in Human Omental Microvascular Endothelial Cells via Activation of the ERK1/2 Pathway.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180831123951
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β-catenin Signaling.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191118113220
The clinical prognostic value of LRG1 in esophageal squamous cell carcinoma.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190204095942
Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191007112516
Cordycepin Downregulates Cdk-2 to Interfere with Cell Cycle and Increases Apoptosis by Generating ROS in Cervical Cancer Cells: in vitro and in silico Study.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180905095356
A Comprehensive Review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180706164536
Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009617666170623115846
Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180628102247
Effects of Intermittent Hypoxia on Expression of Glucose Metabolism Genes in MCF7 Breast Cancer Cell line.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191116095847
Gene Therapy and Photothermal Therapy of Layer-by-Layer Assembled AuNCs /PEI/miRNA/ HA Nanocomplexes.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666181016144855
Cancer stem cells equipped with powerful hedgehog signaling and better epigenetic memory: Avenues to look for cancer therapeutics.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190808155432
Polyisoprenylated cysteinyl amide inhibitors deplete K-Ras and induce caspase-dependent apoptosis in lung cancer cells.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190325144636
Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666171129222159
Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180430125201
Anti-tumor activity of propofol: A focus on microRNAs.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191023100046
Anti-cancer effects of curcumin on myelodysplastic syndrome through the inhibition of enhancer of zeste homolog-2 (EZH2).
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190212121735
Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190115142858
In Silico Structure Modeling and Molecular Docking Analysis of Phosphoribosyl Pyrophosphate Amidotransferase (PPAT) with Antifolate Inhibitors.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666181127115015
Mutational testing in gastrointestinal stromal tumor.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190326123945
Disintegrin tablysin-15 suppresses cancer hallmarks in melanoma cells by blocking FAK/Akt/ERK and NF-κB signaling.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009620666200101094736
Magnesium-dependent phosphatase (MDP) 1 is a potential suppressor of gastric cancer.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190620112546
Novel mechanistic insights into the anti-cancer mode of arsenic trioxide.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191021122006
Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190326120833
Ellipticine, its Derivatives: Re-Evaluation of Clinical Suitability with the Aid of Drug Delivery Systems.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190927150131
The role of Shcbp1 in signaling and disease.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190620114928
Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications.
来源期刊：Current cancer drug targetsDOI：10.2174/1871525717666190717162646
Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180628101059
Malignant Intracranial High Grade Glioma and Current Treatment Strategy.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180530090922
Mechanisms and Treatment Progress of Rituximab-Resistance in Diffuse Large B-cell Lymphoma.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190126125251
Nordihydroguaiaretic Acid in Therapeutics: Beneficial to Toxicity Profiles and the Search for its Analogs.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191022141547
Advance In-silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190320102238
Combinatorial inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant pheochromocytom.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190206120615
Cytoprotective Agents to avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190326120457
HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666181001102557
PPARγ Agonists in Combination Cancer Therapies.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191209102015
Conjugation of Phthalocyanine Photosensitizer with Poly(amidoamine) Dendrimer: Improved Solubility, Disaggregation and Photoactivity Against HepG2 Cells.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180706164046
Isolation, solid-state structure determination, in silico and in vitro anticancer evaluation of an indole amino acid alkaloid L-Abrine†.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666190111111937
Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180430124738
Well-defined graphene oxide as a potential component in lung cancer therapy.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009619666191021113807
The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests.
来源期刊：Current cancer drug targetsDOI：10.2174/1568009618666180817095331

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

AAPS Journal封面

AAPS Journal

学科领域：医学
影响因子：3.7
中科院分区： 3区
AAPS PHARMSCITECH封面

AAPS PHARMSCITECH

学科领域：医学
影响因子：4
中科院分区： 3区
Academic Pediatrics封面

Academic Pediatrics

学科领域：医学
影响因子：2.8
中科院分区： 3区
ACTA ANAESTHESIOLOGICA SCANDINAVICA封面

ACTA ANAESTHESIOLOGICA SCANDINAVICA

学科领域：医学
影响因子：2
中科院分区： 3区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学3区
ONCOLOGY 肿瘤学
4区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
否
否